Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 6 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

Acetazolamide a promising treatment for sleep apnoea

25 Aug 2020

Short-term treatment with acetazolamide appears beneficial to patients with either central (CSA) or obstructive sleep apnoea (OSA), exerting favourable effects on the apnoea-hypopnoea index (AHI) and several patient-centred outcomes, including sleep quality and subjective symptoms, as shown in a study.

Researchers conducted a systematic review and meta-analysis of 28 studies evaluating the effect of oral acetazolamide in patients with OSA/CSA. About one-third of studies were conducted in Asia. In total, 542 patients were in the active treatment group and 553 were in the control group. Mean age ranged from 31 to 69 years, while mean body mass index varied between 21.9 and 38.3kg/m2.

Acetazolamide doses ranged from 36 to 1,000 mg/day, with treatment lasting between 1 and 90 days (median, 6 days). Compared with control, acetazolamide lowered the AHI overall by –0.7 effect sizes (95 percent confidence interval [CI], –0.83 to –0.58; I2, 0 percent; moderate quality of evidence), which corresponded to a reduction of 37.7 percent (95 percent CI, –44.7 to –31.3) or 13.8/h (95 percent CI, –16.3 to –11.4).

The AHI reduction was similar in OSA and CSA patients, but significantly greater with higher doses (at least up to 500 mg/day).

Notably, reductions in AHI were accompanied by improvements in SpO2 nadir (4.4 percent, 95 percent CI, 2.3–6.5; I2, 63 percent; no evidence of effect modification; very low quality of evidence) and several secondary outcomes including sleep quality measures and blood pressure (mostly low quality of evidence).

Based on the present data, the researchers pointed out that future studies may use acetazolamide at 125–500 mg/day (1–2 doses/day; evening dose 2 hours before bedtime) with close follow-up to rule out worsening of sleep apnoea. They added that it would take a few days to achieve the maximal effect for a given dose.

Common side effects, such as paraesthesia, were dose-dependent, so it would be practical to start with 3.5 mg/kg body weight or 125–250 mg/day and titrate up every 3–5 days as needed and tolerated, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 6 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.